2 Epidemiology of SCCHNSquamous cell carcinoma of the head and neck (SCCHN): new cases in Europe annuallySCCHN: mortality in Europe is annuallySCCHN accounts for 6% of all malignanciesWorldwide annual incidence of SCCHN: new patients; deathsGLOBOCAN 2002 (

8 Lessons Learned from Meta-Analysis of Chemotherapy Trials over YearsConcurrent Chemotherapy Improves Survival by 8-11%.Platinum Monotherapy is Preferred.Little Role in Pure Neoadjuvant or Adjuvant Fashions.

16 Prognostic & Predictive Importance of EGFR Over expression:> 90% of all HNSCC Patients.Poor Response to ttt with Chemo-Radiotherapy Through Repopulation of Clonogenic Cells during ttt.Compromised L.C., DFS, OAS.Associated with Cisplatin-Resistance.

28 ERBITUX+RT provides a high reduction in the risk of death at 5 yearsComparison of the reduction in the risk of death (MACH-NC meta-analyses, Bonner study)ERBITUX+RT provides a high reduction in the risk of death at 5 yearsAdjuvant CT+RT1Neoadjuvant CT+RT1Concomitant CT+RT1ERBITUX +RT20%-5%-2%-5%-10%-15%-20%-19%-25%-30%-27%1) Pignon JP, et al. Lancet 2000;355:949–9552) Bonner J.A, et al. ASTRO 2008